DISEASE INDICATIONS: Familial chylomicronemia syndrome (FCS)

MANUFACTURER: Akcea Therapeutics Ireland Limited

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Waylivra is a new RNA-targeted therapy that aims to inhibit the production of a protein that is key to fat metabolism, called ApoC-III, in order to lower triglyceride levels and reduce the associated health risks of familial chylomicronemia syndrome (FCS). Waylivra is administered by subcutaneous injection once a week, in conjunction with a low-fat diet and other lipid-lowering therapies as needed, and was approved by the US FDA in 2019.